Boston, Massachusetts, United States, December 2024 – Medicilon, a leading preclinical contract research organization (CRO), is pleased to announce the appointment of Dr. Lilly Xu as its new Chief Technology Officer (CTO). With over 30 years of expertise in early drug discovery and development, Dr. Xu will spearhead Medicilon’s technological advancements and drive its international growth, further elevating its R&D capabilities.
Dr. Xu earned her Ph.D. in Biology from St. Louis University and is renowned for her pioneering work in human hepatocyte isolation, drug metabolism, and exploratory toxicology. She has successfully led numerous global drug development programs from early discovery through clinical stages. Her career includes leadership roles at major pharmaceutical and biotech companies, including Amgen and Sanofi.
“We are delighted to welcome Dr. Xu at this pivotal moment in Medicilon’s expansion,” said Dr. Chunlin Chen, Founder and CEO of Medicilon. “Her deep expertise and global perspective align perfectly with our vision of driving innovation and accelerating our international growth.”
“I’m thrilled to join Medicilon’s forward-thinking team,” said Dr. Lilly Xu. “I look forward to supporting our global clients by leveraging Medicilon’s extensive preclinical resources, fostering platform innovation, and helping expedite the transition of groundbreaking research into clinical successes that ultimately benefit patients worldwide.”
Medicilon continues to strengthen its discovery research platforms—including chemistry, discovery biologics, and pharmacology—fortifying its position as a leader in preclinical drug discovery and development.
About Medicilon Inc.
Medicilon Inc. is a one-stop preclinical CRO with a proven track record of supporting the approval of 544 IND applications for clinical trials worldwide. The company offers an integrated platform that covers key technologies in drug discovery, pharmaceutical research, and preclinical research. With extensive experience serving domestic and international biomedical industries, Medicilon provides comprehensive preclinical R&D services to advance the global biomedical landscape.
Read Also : Entering 2025, TA Leaders’ Success Built on More than Just Hiring, Says The Josh Bersin Company
People Analytics Teams Still Struggle to Deliver Business Impact, Warns The Josh Bersin Company
ESG and Women’s Leadership: Driving Sustainability and Inclusion
Learning and Development Trends for 2025: Shaping the Future of Workplace Learning
